Primary Care Diabetes
Volume 1, Issue 2 , Pages 103-105 , June 2007

Gut hormones, incretin mimetics and gliptins: New understanding and novel therapies in type 2 diabetes

  • Neil M. Munro

      Affiliations

    • Capelfield Surgery, Elm Road, Claygate, Surrey KT10 0SA, UK
    • Corresponding Author InformationCorresponding author.
    • ,
  • Jonathan C. Levy

      Affiliations

    • Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, UK

Received 10 April 2007 ,Accepted 10 April 2007.

References 

  1. Drucker DJ. Unraveling the complexities of gut endocrinology. Nat. Clin. Pract. Endocrinol. Metab. 2007;3(4):317
  2. Elrick H, Stimmler L, Hlad CJ, et al. Plasma insulin response to oral and intravenous glucose administration. J. Clin. Endocrinol. Metab. 1964;24:1076–1082
  3. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J. Clin. Invest. 1967;46:1954–1962
  4. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46–52
  5. Rudovich A, Kaiser S, Engeli S, Pfeiffer AFH. Gastric inhibitory polypeptide receptors are present in human subcutaneous adipose tissue: effects of central obesity and weight loss. In: Programme and Abstracts of the European Association for the Study of Diabetes 41st Annual Meeting. September 12–15, Athens, Greece. 2005;(Abstract 549)
  6. Vilsboli T, Holst JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia. 2004;47(3):357–366
  7. Triplitt C, Wright A, Chiquette E. Incretin mimetics and dipeptidyl peptidase-1V inhibitors: potential new therapies for type 2 diabetes mellitus. Pharmacotherapy. 2006;26(3):360–374
  8. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet. 2006;38(3):320–323
  9. Eng J, Kleiman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 1992;267(11):7402–7405
  10. Levy JC. Therapeutic intervention in the GLP-1 pathway in Type 2 diabetes. Diabetic Med. 2006;23(s1):14–19
  11. Orskov C, Poulson SS, Moller M, Holst JJ. Glucagon-like peptide receptors in the subfornical organ and the area postrema are accessible to circulating glucagons-like peptide 1. Diabetes. 1996;45(6):832–835
  12. Idris I, Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diabet. Obesity Metab. 2007;9(2):153–165
  13. Chyan Y-J, Chuang L-M. Dipeptidyl peptidase-IV inhibitors: an evolving treatment for type 2 diabetes from the incretin concept endocrine. Metab. Immune Drug Discov. 2007;1(1):15–24
  14. Deacon CF. Therapeutic strategies based on glucagon-like peptide 1. Diabetes. 2004;53(9):2181–2189
  15. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycaemic control over 30 weeks in sulphonylurea treated patients with type 2 diabetes. Diabet. Care. 2004;27(11):2628–2635
  16. DeFronzo RA, Ratner R, Han J, Kim D, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycaemic control over 30 weeks in metformin treated patients. Diabet. Care. 2005;28:1092–1100
  17. Kendall DM, Riddle MC, Rosentock J, et al. Effects of exenatide (exendin-4) on glycaemic control over 30 weeks in patients treated with metformin and a sulphonylurea. Diabet. Care. 2005;28:1083–1091
  18. Dejager S, Lebault A, Couturier A, Schweizer A. Sustained reduction in HbA1cs during one-year treatment with vildagliptin in patients with type 2 diabetes. In: Program and Abstracts of the American Diabetes Association 66th Scientific Sessions. June 9–13, Washington, DC. 2006;(Abstract 120-OR)
  19. Riddle MC, Henry RR, Poon TH, et al. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabet. Metab. Res. Rev. 2006;22(6):483–491
  20. Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabet. Metab. Res. Rev. 2004;20(5):411–417

PII: S1751-9918(07)00039-3

doi: 10.1016/j.pcd.2007.04.003

Primary Care Diabetes
Volume 1, Issue 2 , Pages 103-105 , June 2007

Article Tools